Clinical Trials
2 trialsNCT01804686 2026-06-05
CAN3001
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT03112603 2025-08-12
A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)
Incyte Corporation
Phase 3 Completed